Investigation of the effect of levothyroxine treatment on serum lipids in patients with mild hypothyroidism

Number of pages: 95 File Format: word File Code: 32100
Year: Not Specified University Degree: PhD Category: Medical Sciences
  • Part of the Content
  • Contents & Resources
  • Summary of Investigation of the effect of levothyroxine treatment on serum lipids in patients with mild hypothyroidism

    Dissertation for the degree of Doctor of General Medicine

    Abstract:

    Title: Investigating the effect of treatment with levothyroxine on serum lipids in patients with mild hypothyroidism

    Introduction:

    Mild hypothyroidism is the biochemical evidence of thyroid hormone deficiency in patients whose clinical features of hypothyroidism are very minor or not present at all. In these patients, at the same time, a slight increase in serum TSH level can be seen.

    Given that a slight increase in TSH level causes fat metabolism disorder, dyslipidemia in these patients can be the cause of cardiovascular problems in them. Our study investigated the effect of early treatment with levothyroxine on serum lipids in patients with mild hypothyroidism. Materials and methods: During this randomized clinical trial, 82 patients with subclinical hypothyroidism from the outpatient clinic of Shahid Beheshti Hospital in Qom were randomly examined. who had a normal serum T4 level and a serum TSH level>5.2 mu/L. The baseline level of serum lipids of the patients was measured, and then the patients were randomly divided into two groups, the control and the case, and for the treated group, treatment with levothyroxine was started for three months, and then the patients of both groups were re-evaluated.

    Results:

    Average age in the case group 68.39 and in the control group it was 63.37. After 3 months of treatment with levothyroxine in the intervention group, the amount of T4 increased significantly and the amount of TSH, TG, chol, LDL HDL, decreased significantly. Mild thyroid can significantly reduce the serum level of LDL, TG, chol.

    Key words: mild hypothyroidism, levothyroxine, lipid

    Chapter one:

    Research introduction

    1-1: expression Issue:

    By definition, the term subclinical hypothyroidism is generally used to describe patients with normal FT4 levels and mildly elevated serum TSH levels. Other terms used for these conditions; Mild hypothyroidism is preclinical hypothyroidism or reduced thyroid reserve. The amount of TSH increase in these patients is low and is around 10-4 mu/L. (1)

    In fact, mild hypothyroidism is the biochemical evidence of thyroid hormone deficiency in patients whose clinical features of hypothyroidism are very minor or not present at all. In these patients, at the same time, a slight increase in the serum level of TSH can be seen. (1)

    Although mild hypothyroidism is often asymptomatic, 30% of patients have evidence that suggests thyroid hormone deficiency. One of the side effects and at the same time mild hypothyroid symptoms is the impact on cardiopulmonary function. In a study conducted in this field, it is stated that: Myocardial function is disturbed in patients with mild hypothyroidism and mild hypothyroidism has been evaluated as a risk factor for cardiovascular diseases. In various studies, it has been clearly emphasized that dyslipidemia caused by mild hypothyroidism is the main cause of cardiovascular problems in these patients. (2).

    Approaches that have been published recently, the treatment of patients is not recommended until their TSH level is below 10 mu/L, and dyslipidemia is not considered as one of the indications for treatment. (1)

    At the same time, dyslipidemia also exists in this group of patients and can be the cause of cardiovascular problems in these patients. Therefore, approaching this research and considering that the importance of dyslipidemia in mild hypothyroid patients and the effects of thyroid hormone replacement on lipids are still controversial, and in a number of studies conducted in recent years, treatment with levothyroxine in mild hypothyroid patients has been able to reduce serum LDL levels and improve cardiac function.. Therefore, approaching this research and taking into account that the importance of dyslipidemia in mild hypothyroid patients and the effects of thyroid hormone replacement on lipids are still controversial, and in a number of studies conducted in recent years, treatment with levothyroxine in mild hypothyroid patients has been able to reduce serum LDL levels and improve heart function (3,4), but on the other hand, in a significant number of studies, treatment of such patients with levothyroxine significantly reduced serum total cholesterol levels. or did not follow LDL (5)

    In addition, the existence of such contradictory results in this issue also raises the importance of other factors affecting dyslipidemia, including race and ethnicity, and environmental effects, as in some studies, the effect of gene factors on the development and response to treatment of dyslipidemia in mild hypothyroid patients has been proven (6)

    Therefore, considering the rare number of studies Similar in this field in the country and the absence of a similar study in the city of Qom, we considered it necessary to investigate this issue in a study whether treatment with levothyroxine in patients with mild hypothyroidism whose serum TSH level is below 10 mu/L and who do not have other indications for treatment with levothyroxine including (anti-TPO positive, pregnancy, suffering from goiter) can reduce the serum lipid level in patients. No.

    Certainly proving that treatment with levothyroxine reduces serum lipid levels in mild hypothyroid patients will play an important role in preventing cardiovascular diseases, improving health and quality of life in this category of patients.

     

     

     

     

     

     

     

    1-2 goals Research:

    main objective:

    determine the effect of treatment with levothyroxine on serum lipids in patients with mild hypothyroidism

    sub-objectives:

    1. Determination of the average level of serum TG, LDL, HDL before treatment with levothyroxine in the intervention group

    2. Determination of the average level of serum TG, LDL, HDL before starting the study in the control group

    3. Determination of the average level of serum TG, LDL, HDL after treatment with levothyroxine in the intervention group

    4. Determining the average level of serum TG, LDL, HDL after completing the study in the control group

    5. Comparison of the average level of serum TG, LDL, HDL before and after treatment in the intervention group

    6.  Comparison of the average level of serum TG, LDL, HDL before and after the completion of the study in the control group

    7. Comparison of the average levels of serum TG, LDL, and HDL before and after treatment in the control and intervention groups

    -3 research questions:

    1. What is the average level of serum TG, LDL, HDL before treatment with levothyroxine in the intervention group?

    2. What is the average level of serum TG, LDL, HDL at the beginning of the study in the control group?

    3. What is the average level of serum TG, LDL, HDL after treatment with levothyroxine in the intervention group?

    4. What is the average level of serum TG, LDL, HDL at the end of the study in the control group? rtl;"> 

     

     

     

     

     

     

     

     

     

     

     

     

     

    Assumptions Research:

    1. The levels of TG, LDL, and HDL serum before and after treatment are different in the intervention group

    2

  • Contents & References of Investigation of the effect of levothyroxine treatment on serum lipids in patients with mild hypothyroidism

    List:

    Chapter One: Introduction to Research.1

    1-1 Statement of the Problem: 2

    1-2 Research Objectives.5

    1-3 Research Questions and Assumptions.6

    Chapter Two: Knowledge Available in Research.7

    1-2 Part One: Conceptual Framework.8

    2-1-1 Gland Thyroid. 8.

    2-1-2 Hypothyroidism. 17

    2-1-3 Dyslipidemia. 28

    2-2 Part Two: Review of the studies done. Sixth: conclusions and suggestions. 75

    Resources..76

     

    Source:

     

    Dan. Longo, Anthony S. Fauci, Dennis L. Kasper, Stephen L. Hauser, J. Larry Jameson, Joseph Loscalzo, et al. Harrison's Principles of Internal Medicine. 18th ed. Tehran: Andishe Rafi; 1388. p. 477-499. [Text in Persian]

    Michael T. McDermott. E. Chester Ridgway. subclinical hypothyroidism is mild thyroid failure and should be treated.   The journal of clinical endocrinology & metabolism. 2001;32:123.

    Charles j.Glueck.Cholesterol. center jewish hospital.

    4. B.A. ryff.De leche.Jestaube.et al. LDL/HDL-change in subclinical hypothyroidism: possible risk factors for coronary heart disease. Department of internal medicine, university hospital of Basel ch-4031. [serialonline].

    5. Teixeria PFS. Reuters VS. Ferreira MM. et al. Treatment of subclinical hypothyroidism reduces atherogenic lipid levels in a placebo-controlled double-blind clinical trial. Department de medicina intera. Hospital de terrassa. [serialonline].

    6. Wiseman SA, Powell JT, Humphries SE, Press M. The magnitude of the hypercholesterolemia of hypothyroidism is associated with variation in the low density lipoprotein receptor gene. J Clin Endocrinol Metab. 1993 Jul;77(1):108

    7. Shlomo Melmed, Kenneth S. Polonsky, MD, P. Reed MD Larsen and Henry M. Kronenberg. Williams text book of endocrinology. 12th edition. Chapter 12.893-7

    8. Baliant Kacsoh. Endocrine physiology. first ed. Mc Graw - Hill. 2008. p. 202-213

    9. Ganoge W.F.Review of medical physiology.2 ed.Parentic-Hall.2004.p.1677-79

    10.  Moradi sedighe, Hedaiati Mahdi, Azizi fereidun. Effect of LT4 treatment on clinical and laboratory findings in subclinical hypothyroidism patients. Iran`s endocrine and metabolism magazine. 2004;1:27-28

    11. Shahbazian Hajie, Mohammadi Somaye, et al. Effect of 6 months L-thyroxin therapy on lipid profile of subclinical hypothyroidism. Department of endocrinology Ahvaz. 2009;87:22

    12. Razavi s. Ingoe L. Keeka G. the beneficial effect of L-thyroxin on cardiovascular risk factors. endothelial function. and quality of life in subclinical hypothyroidism. the journal of Queen Elizabeth Hospital, United Kingdom. 2009 October; 24:145

    13. Tunbridge WM, Evered DC, Hall R, Bird T, Evans JG, French JM, Young E. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf). 1977; 7:481– 493

    14. Sawin CT, Chopra D, Azizi F, Mannix JE, Bacharach P 1979 The aging thyroid. Increased prevalence of elevated serum thyrotropin levels in the elderly. JAMA. 242:247–250

    15. Ineck BA, Ng TM. Effects of subclinical hypothyroidism and its treatment on serum lipids. Ann Pharmacother. 2003 May;37(5):725-30.

    16.Bastenie PA, Vanhaelst L, Neve P. Coronary-artery disease in hypothyroidism. Lancet. 1967 Dec 9;2(7528):1221-2.

    17. Fowler PS, Swale J. Premyxoedema and coronary-artery disease. Lancet. 1967 May 20;1(7499):1077-9.

    18. Monzani F, Caraccio N, Kozàkowà M, Dardano A, Vittone F, Virdis A, Taddei S, Palombo C, Ferrannini E. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2004 May;89(5):2099-106.

    19. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, Drewe J, Huber P, Herzog R, Müller B. TSH-controlled L-thyroxine therapy reducesTSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab. 2001 Oct;86(10):4860-6.

    20. Iqbal A, Jorde R, Figenschau Y. Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Troms? Study. J Intern Med. 2006 Jul;260(1):53-61

    21. Pazos F, Alvarez jj, Rubies-part j, et all. Long term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins. J clin endocrine metab 1995;80:562.

    22. Ito M, Arishima T, Kudo T, et al. Effect of levo-thyroxin replacement on non-high-density lipoprotein cholesterol in hypothyroid patients. J Clin Endocrinal metab 2007;92:608

    23. de Brulin TW, Van barlingen H, Van Linde-sibenius Trip M. et all. Lipoprotein (a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid and hyperthyroid subjects. J clin endocrinal metab 1993;76:121.

    24. Martinez-Triguero ML, Hernandez-Mijares A, Nguyen TT, et al. Effect of thyroid hormone replacement on lipoprotein(a). lipid and apolipoprotein in subjects with hypothyroidism. Myo Clin proc 1998;73:837

    25. Gilbert A. Geraldo Medeiros-neto, Juliana C Vinagre, et al. Lipid metabolism in subclinical hypothyroidism. 2011;21:4

    26. Efstathiadou Z, Bitsis S, Milionis HJ, et al. lipid profile in subclinical hypothyroidism. Eur J Endocrinol 2001;145:705-10

    27. Ross DS 2000 Subclinical hypothyroidism. In: Braverman LE, Utiger RU, eds. Werner and Ingbar's the thyroid, 8th Ed. New York: Lippincott-Williams & Wilkins; 1001–1006

    28. Ito M, Takamatsu J, Masuo T, et al. Serum concentration of remnant-like particles in hypothyroid patients before and after thyroxine replacement. Clin Endocrinal (oxf)2003;58:621

    29. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008:29:76

    30. Surk MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J clin Endocrinol metab 2007:92:4575.

    31. Mc Dermott MT, Ridgway EC, subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol metab 2001:86:4585.

    32. Gharib H, Tuttle RM, Baskin HJ, et al. subclinical thyroid dysfunction: a joint statement on management from the American association of clinical endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab 2005:90:581.

    33. Cooper DS, Halpren R, Wood LC, Levin AA, Ridgway EC. L-Thyroxin therapy in subclinical hypothyroidism. Ann intern med1984;101:18-24

    34. Bemben DA, Winn P, Hamm RM, Morgan L et al. Thyroid disease in the elderly. part 1. prevalence of undiagnosed hypothyroidism. J Fam Pract 1994;38:577-82

    35. Serter R. Demirbas B, Cakal E, Aral Y. The effect of L-thyroxin replacement therapy on lipid based cardiovascular risk in subclinical hypothyroidism. J Endocrinol Invest 2004;27(10):897-903

    36. Keventy J, Heldgaard PE, Gram J et al. Subclinical hypothyroidism is associated with low-grade inflammation, increased triglyceride level and predicts cardiovascular disease. Clin Endocrinol(oxf) 2004;61(2):223-8

    37. Haggerty JJ Jr, Evans DL, Prange A et al. Organic brain syndrome associated with marginal hypothyroidism. AMJ psychologyn1986;143:785-6

    38. Friedwald WT, Levy RI. Estimation of the concentration of low-density lipoprotein cholesterol in plasma.

Investigation of the effect of levothyroxine treatment on serum lipids in patients with mild hypothyroidism